Ge Huang1, Dan Yao1, Xiaoli Yan1, Mingyu Zheng2, Ping Yan1, Xiaoxia Chen1, Dan Wang3. 1. Department of Gynecology and Obstetrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China. 2. Department of Pharmacy, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China. 3. Department of Gynecology and Obstetrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China. swh_wang@163.com.
Abstract
INTRODUCTION: Despite intensive research, preterm birth (PTB) rates have not decreased significantly in recent years due to a lack of understanding of the underlying causes and insufficient treatment options for PTB. We are committed to finding promising biomarkers for the treatment of PTB. METHODS: An extensive search of the literature was conducted with MEDLINE/PubMed, and in total, 151 studies were included and summarized in the present review. RESULTS: Substantial evidence supports that the infection and/or inflammatory cascade associated with infection is an early event in PTB. Toll-like receptor (TLR) is a prominent pattern recognition receptor (PRR) found on both immune and non-immune cells, including fetal membrane cells. The activation of TLR downstream molecules, followed by TLR binding to its ligand, is critical for infection and inflammation, leading to the involvement of the TLR signaling pathway in PTB. TLR ligands are derived from microbial components and molecules released by damaged and dead cells. Particularly, TLR4 is an essential TLR because of its ability to recognize lipopolysaccharide (LPS). In this comprehensive overview, we discuss the role of TLR signaling in PTB, focus on numerous host-derived genetic and epigenetic regulators of the TLR signaling pathway, and cover ongoing research and prospective therapeutic options for treating PTB by inhibiting TLR signaling. CONCLUSION: This is a critical topic because TLR-related molecules and mechanisms may enable obstetricians to better understand the physiological changes in PTB and develop new treatment and prevention strategies.
INTRODUCTION: Despite intensive research, preterm birth (PTB) rates have not decreased significantly in recent years due to a lack of understanding of the underlying causes and insufficient treatment options for PTB. We are committed to finding promising biomarkers for the treatment of PTB. METHODS: An extensive search of the literature was conducted with MEDLINE/PubMed, and in total, 151 studies were included and summarized in the present review. RESULTS: Substantial evidence supports that the infection and/or inflammatory cascade associated with infection is an early event in PTB. Toll-like receptor (TLR) is a prominent pattern recognition receptor (PRR) found on both immune and non-immune cells, including fetal membrane cells. The activation of TLR downstream molecules, followed by TLR binding to its ligand, is critical for infection and inflammation, leading to the involvement of the TLR signaling pathway in PTB. TLR ligands are derived from microbial components and molecules released by damaged and dead cells. Particularly, TLR4 is an essential TLR because of its ability to recognize lipopolysaccharide (LPS). In this comprehensive overview, we discuss the role of TLR signaling in PTB, focus on numerous host-derived genetic and epigenetic regulators of the TLR signaling pathway, and cover ongoing research and prospective therapeutic options for treating PTB by inhibiting TLR signaling. CONCLUSION: This is a critical topic because TLR-related molecules and mechanisms may enable obstetricians to better understand the physiological changes in PTB and develop new treatment and prevention strategies.
Authors: Roberto Romero; Nardhy Gomez-Lopez; Andrew D Winters; Eunjung Jung; Majid Shaman; Janine Bieda; Bogdan Panaitescu; Percy Pacora; Offer Erez; Jonathan M Greenberg; Madison M Ahmad; Chaur-Dong Hsu; Kevin R Theis Journal: J Perinat Med Date: 2019-11-26 Impact factor: 1.901
Authors: Lisa M Rogers; Anjali P Anders; Ryan S Doster; Elizabeth A Gill; Juan S Gnecco; Jacob M Holley; Tara M Randis; Adam J Ratner; Jennifer A Gaddy; Kevin Osteen; David M Aronoff Journal: Am J Reprod Immunol Date: 2018-08-07 Impact factor: 3.886
Authors: C Iavazzo; K Tassis; D Gourgiotis; M Boutsikou; S Baka; D Hassiakos; A Hadjithomas; D Botsis; A Malamitsi-Puchner Journal: Arch Gynecol Obstet Date: 2009-06-25 Impact factor: 2.344
Authors: Natalie Suff; Rajvinder Karda; Juan A Diaz; Joanne Ng; Julien Baruteau; Dany Perocheau; Mark Tangney; Peter W Taylor; Donald Peebles; Suzanne M K Buckley; Simon N Waddington Journal: Am J Pathol Date: 2018-07-21 Impact factor: 4.307
Authors: Natalie Suff; Rajvinder Karda; Juan Antinao Diaz; Joanne Ng; Julien Baruteau; Dany Perocheau; Peter W Taylor; Dagmar Alber; Suzanne M K Buckley; Mona Bajaj-Elliott; Simon N Waddington; Donald Peebles Journal: Front Immunol Date: 2020-02-11 Impact factor: 7.561